Copper-peptide research, topical and beyond.
GHK-Cu is a copper-binding tripeptide first isolated from human plasma in 1973. Small topical studies in people have looked at skin appearance; data on the injected form is scarce.
- Evidence grade or review status for every compound
- Sources listed on every page
- US and sport status, dated
Compounds studied in this area
Grades describe the published evidence, not a promise of any effect.
What has been studied
GHK was isolated from human plasma in 1973; its copper complex was characterised later. [1]
Small topical studies in people have looked at skin appearance. We found no controlled trial of injected GHK-Cu, published or registered, when we checked PubMed and ClinicalTrials.gov in November 2026. [1] [3]
The FDA says compounded injectable GHK-Cu may carry a risk of immune reactions, because of possible aggregation and peptide-related impurities, and that there are limited data in humans to inform its safety. [2]
How far the research has gone
Pick a compound to see the highest rung reached, from cell study to approval.
What the research does not show
Saying what we don't know is part of the evidence.
Any effect of injected GHK-Cu in people from a controlled trial.
Results for any person: the topical studies measured skin outcomes in small groups.
Where it stands legally
As of November 2026. See the full tracker and the changelog.
| Compound | FDA approval | 503A compounding (2026) | WADA (2026 List) |
|---|---|---|---|
| GHK-Cu | Not approved | Injectable form formerly FDA Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); not in the July review | Not named; S0 covers unapproved substances |
Worth knowing
Research use only
None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.
What research use only meansNo doses, ever
We publish no doses, protocols, or cycles for people, on any page.
Why we publish no dosesHow we grade evidence
Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.
Evidence gradesQuestions people ask
Is topical GHK-Cu different from injected GHK-Cu?
Yes, in the evidence. Small topical studies in people have looked at skin appearance; we found no controlled trial of the injected form.
Why is GHK-Cu blue?
The copper in the complex gives it its colour. Colour is not proof of identity: a lab report should confirm identity by mass.
Sources
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- PubMed (clinical-trial filters) and ClinicalTrials.gov searches for controlled trials of injected GHK-Cu (terms GHK-Cu, Cu-GHK, GHK Cu, copper tripeptide-1, prezatide), 18 November 2026: none found. clinicaltrials.gov/search?term=GHK-Cu
- World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
Related pages
Start with the evidence
Every page sourced and dated, including what the research does not show.
Open the research library